Voyageur Pharmaceuticals Expands into Mexican Healthcare Market Through Distribution Partnership

Voyageur Pharmaceuticals Ltd. has signed a Non-Exclusive Distribution Agreement with PHALANX, Comercializadora e Importadora de Componentes SA DE CV, marking a strategic expansion into Mexico's healthcare sector. This partnership follows a non-binding Letter of Intent announced in June 2025 and establishes a framework for distributing Voyageur's barium-based contrast media products throughout Mexico.

Under the agreement, PHALANX will lead the registration of Voyageur's barium contrast media products with Mexican health regulatory authorities and distribute these products through its established network. Voyageur will provide comprehensive support throughout the regulatory approval and commercialization process, working collaboratively to advance market access. This partnership aligns both companies in a shared vision to establish and grow Voyageur's market presence within Mexico's medical imaging and contrast media markets.

PHALANX brings significant expertise to this collaboration as a leading pharmaceutical distributor with a strong presence in Mexico and key Latin American markets. The company provides comprehensive commercial intelligence and strategic market solutions for businesses entering the region, combining rigorous market analysis with hands-on operational execution. PHALANX's capabilities include deep regulatory expertise, precise supply chain management, and actionable market insights that accelerate international expansion while minimizing risk.

This partnership represents a key milestone in Voyageur's international growth strategy, further expanding the company's global footprint and supporting access to underserved markets with increasing demand for high-quality contrast media. Brent Willis, CEO of Voyageur, stated that this agreement marks a significant step forward in the company's commercialization roadmap and reflects continued commitment to expanding global access to innovative, cost-effective imaging solutions. He emphasized that Latin America represents a critical market in Voyageur's expansion plan, with this partnership laying the groundwork for long-term growth.

The distribution agreement builds on Voyageur's broader strategic focus on vertically integrating the barium and iodine contrast markets. The company is developing barium and iodine Active Pharmaceutical Ingredients that offer high-performance and cost-effective imaging contrast agents. Voyageur's business plan includes generating cash flow to prove economics for the Frances Creek barium contrast project feasibility study, working with established third-party GMP pharmaceutical manufacturers in Canada to ensure regulatory validation worldwide.

Sales of Voyageur's barium sulfate contrast media products in Mexico and other Latin American countries will be subject to local regulatory approval processes, with PHALANX expected to take the lead in preparing and submitting necessary filings supported by Voyageur's technical and regulatory team. This collaboration leverages PHALANX's decades of experience in the Mexican public health landscape and over 20 years of expertise in iodine and gadolinium contrast media for radiology.

Voyageur's approach to the contrast media market is distinguished by its ownership of the Frances Creek Project, which contains rare and exceptional grade mineral suitable for pharmaceutical applications. The company believes this natural resource will replace current synthetic barium sulfate products in the pharmaceutical marketplace with higher quality imaging products. Voyageur's vision includes becoming the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw material sourcing to final production.

This expansion into Mexico represents more than just market entry; it demonstrates the growing global demand for cost-effective, high-quality medical imaging solutions. The partnership with PHALANX provides Voyageur with established distribution channels and regulatory expertise that could significantly accelerate market penetration while ensuring compliance with local healthcare regulations. For healthcare providers and patients in Mexico, this collaboration could mean improved access to advanced imaging contrast media that enhances diagnostic capabilities while potentially reducing costs.

The Mexican healthcare market represents a substantial opportunity for contrast media providers, with growing demand for medical imaging services and pharmaceutical products. This partnership positions Voyageur to capitalize on this demand while establishing a foundation for potential future expansion throughout Latin America. The collaboration exemplifies how strategic partnerships can bridge international market gaps, combining specialized manufacturing capabilities with local market expertise to deliver innovative healthcare solutions to underserved regions.